Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.
TiGenix’s lead compound Cx601 is a safe and effective long-term treatment of complex perianal fistulas in Crohn’s disease patients, a clinical trial reports. The positive results come from the 104-week ... Read more
Growing evidence suggests that the Mycobacterium avium subspecies paratuberculosis (MAP) is the bacteria that causes Crohn’s disease and that the disease can be transmitted from animals to humans, scientists ... Read more
The first patient has been dosed in MAP US2, an open-label extension clinical trial evaluating RHB-104 as a treatment for Crohn’s disease, according to its maker, RedHill Biopharma. MAP US ... Read more
VHsquared announced the first patients have entered HARBOR, an international Phase 2 clinical trial examining the efficacy of V565 ( an anti-TNFα oral antibody) in treating Crohn’s disease. The study ... Read more
Ferring Pharmaceuticals is collaborating with the Instituto de Ciencias Farmaceuticas (ICF, based in Brazil) to develop a potential new treatment for anal fissures for patients with inflammatory bowel disease (IBD). The ... Read more
Galapagos NV, collaborating with Gilead Sciences, will soon begin recruiting for announced two new Phase 2 clinical trials to evaluate filgotinib in patients with small bowel Crohn’s disease, as ... Read more
Positive interim results were reported in the first two groups of ulcerative colitis patients being treated with Brilacidin (PMX-30063) in a dose-escalating Phase 2 clinical trial. Patients for a third and final group ... Read more